Everence Capital Management’s Emergent Biosolutions EBS Stock Holding History

Everence Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-18,580	Closed	-$219	–	758
2022 Q4	$219	Buy	+18,580	New	+$288K	0.02%	661
2022 Q3	–	Sell	-8,680	Closed	-$269K	–	728
2022 Q2	$269K	Hold	8,680	–	–	0.02%	554
2022 Q1	$356K	Hold	8,680	–	–	0.03%	507
2021 Q4	$377K	Buy	+8,680	New	+$393K	0.03%	515
2020 Q3	–	Sell	-7,680	Closed	-$641K	–	694
2020 Q2	$641K	Hold	7,680	–	–	0.08%	218
2020 Q1	$444K	Buy	7,680 +1,180	+18%	+$68K	0.06%	269
2019 Q4	$351K	Hold	6,500	–	–	0.05%	425
2019 Q3	$340K	Hold	6,500	–	–	0.06%	388
2019 Q2	$314K	Hold	6,500	–	–	0.05%	418
2019 Q1	$328K	Buy	6,500 +2,540	+64%	+$150K	0.06%	376
2018 Q4	$235K	Hold	3,960	–	–	0.05%	339
2018 Q3	$261K	Buy	+3,960	New	+$231K	0.05%	350
2018 Q2	–	Sell	-3,960	Closed	-$208K	–	432
2018 Q1	$208K	Buy	+3,960	New	+$197K	0.05%	386

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Everence Capital Management's EBS Position: Q1 2023 in Review

Everence Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2023, closing a stake of 18,580 shares — an estimated $219 sold.

Everence Capital Management first reported a position in EBS in Q1 2018 and held it in 13 quarters. The position peaked at $641K in Q2 2020. 191 funds tracked by Wall St. Rank hold EBS as of Q1 2023.

Everence Capital Management reported no remaining Emergent Biosolutions position as of Q1 2023 after selling out during the quarter.
Everence Capital Management sold 18,580 Emergent Biosolutions shares in Q1 2023, an estimated $219.
Everence Capital Management first reported a position in Emergent Biosolutions in Q1 2018 and held it in 13 quarters.
Everence Capital Management's Emergent Biosolutions position peaked at $641K in Q2 2020.
191 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2023.

Based on Everence Capital Management's 13F filing for Q1 2023, filed 4 Apr 2023.